Emcure Pharmaceuticals (EMCURE) — Board Meeting

📢 Key Event
Retirement of Chairman Berjis Desai, ratification of cost auditor remuneration, re-appointment of Dr. Mukund Gurjar and Satish Mehta, appointment of Independent Director Raghu Kumar

🔄 What Changed
Re-appointment of Dr. Mukund Gurjar and Satish Mehta; appointment of new Independent Director Raghu Kumar; retirement of Berjis Desai; updated remuneration limits

🔮 What's Next
Low-to-mid-teens revenue growth target for FY2026-27; 75-100 bps EBITDA margin expansion; deleveraging using free cash flow; R&D investment at 4-5% of revenue; capex focus on capacity expansion

💡 Investor Takeaway
The AGM resolutions confirm leadership continuity with new appointments while targeting growth and margin expansion through strategic investments and deleveraging, supporting long-term shareholder value creation.

The 45th Annual General Meeting of Emcure Pharmaceuticals Ltd (BSE: EMCURE) is scheduled for 21 September 2026 via video conferencing. The notice outlines resolutions including the retirement of Chairman Berjis Desai, ratification of cost auditor remuneration, re-appointment of Whole-time Director Dr. Mukund Gurjar and Managing Director & CEO Satish Mehta, and appointment of Independent Director Raghu Kumar. Key financial highlights include FY2025-26 revenue of INR 92,035 Mn, PAT growth of 41%, and EBITDA margin expansion to 19.4%. The company targets low-to-mid-teens revenue growth and 75-100 bps EBITDA margin expansion in FY2026-27, with deleveraging plans using free cash flow. Shareholding stands at 77.87% promoter-held, with 99.99% dematerialization. The meeting will feature e-voting from 18-20 September 2026 via InstaVote, with remote participation options.

📄 View Original Announcement (PDF)

📊 Stock Analysis — EMCURE ✨ Ask AI About This

About Emcure Pharmaceuticals Ltd (EMCURE)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹35,011.16 Cr P/E: 34.6 ROE: 22.9% ROCE: 29.7% Div Yield: 0.20%

View full EMCURE stock details →

📡 Get AI alerts when EMCURE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track EMCURE — Free

💡 Ask AI about this filing

"What is the expected timeline for deleveraging using free cash flow?" "How will the 75-100 bps EBITDA margin expansion be achieved?" "What is the projected revenue growth rate for FY2026-27?"

Ask AI Free →

📊 More EMCURE filings

See all EMCURE filings →

🔥 Also filed on 28 August 2026

BLIL Balmer Lawrie Investment Ltd Annual Report 520075 Samkrg Pistons & Rings Ltd Annual Report 507998 Simmonds Marshall Ltd Annual Report BLUEDART Blue Dart Express Ltd Annual Report TTL T T Ltd Insider Trading LTF L&T Finance Ltd Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when EMCURE files new disclosures

Track EMCURE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track EMCURE — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd